New India Drug Price Caps Narrowed To Three Options
This article was originally published in PharmAsia News
Executive Summary
Indian price regulators are considering three types of maximum charges for two-thirds of pharmaceuticals not already controlled. One possibility is to cap the trade margin at 300 percent of the manufacturer's price instead of the current 2,900 percent. Another option considered is setting the cap at 50 percent or 70 percent of the leading brand in each category, an option opposed by the National Pharmaceutical Pricing Authority. A third option would set the top price at 15 percent of the printed maximum retail price, 35 percent for retailers. (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.